Bringing drugs to market requires a lot of money. And the whole process takes a long time (order of a decade).
Subsidizing the tests or doing more marketing would sell more tests, but wouldn't speed up drug development. And doing so would burn up money that could be used for drug development.
And even though the licensing deal is promising, there has been no drug brought to market yet based on 23andMe's data. So it's a hard sell to investors.
Subsidizing the tests or doing more marketing would sell more tests, but wouldn't speed up drug development. And doing so would burn up money that could be used for drug development.
And even though the licensing deal is promising, there has been no drug brought to market yet based on 23andMe's data. So it's a hard sell to investors.